Regeneron Pharmaceuticals Trading Volume Drops 57.7% to $485 Million Despite Strong Financial Health

On June 23, 2025, Regeneron Pharmaceuticals, Inc. (REGN) saw a trading volume of $485 million, marking a 57.7% decrease from the previous day. The stock closed with a slight increase of 0.37%.

Analysts have noted a shift in Regeneron's growth strategy, as the company's reliance on Eylea has diminished. This change reflects a broader adjustment in the company's approach to growth and development.

Regeneron reported revenues of $3.03 billion for the quarter ending March 31, 2025, a 3.7% decrease year over year. This revenue figure fell short of analysts' expectations by 6.1%, contributing to a disappointing quarterly performance.

Regeneron's financial health is robust, with a quick ratio of 4.03, a current ratio of 4.93, and a debt-to-equity ratio of 0.09. These metrics indicate strong liquidity and a conservative approach to debt management.

Marietta Wealth Management LLC increased its holdings in Regeneron Pharmaceuticals by 30.2% during the first quarter of 2025, demonstrating continued investor confidence in the company's long-term prospects.

Regeneron Pharmaceuticals is actively pursuing FDA approval for two oncology therapeutics, Linvoseltamab and Odronextamab, following previous regulatory setbacks. This effort underscores the company's commitment to advancing its oncology portfolio despite past challenges.